Fact CheckerSign in

NCT04979728Recruiting

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots (HOME-1)

Source: ClinicalTrials.gov · Last updated 3 Mar 2026

Brief summary (registry, in English)

The goal of this observational study is to establish an operational framework for home self-collections of blood samples to be used for antiviral drug concentration measurements. Participants will continue on their prescribed antiviral(s) for HIV treatment or prevention and followed for up to approximately 1 year. The investigators will compare drug concentrations of antivirals and relevant metabolites/anabolites in clinic-collected and self-collected blood samples.

Status (registry)
Recruiting
Study type
Observational
Enrollment
150 (estimated)
First submitted
14 Jul 2021
Start date
27 May 2021
Primary completion date
30 Jun 2027
Lead sponsor
University of Colorado, Denver
Diseases
HIV
NCT number
NCT04979728

What you commit to

  • Study type: Observational
  • Planned participants: 150
  • From 27 May 2021 to the primary completion date, 30 Jun 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Any medical condition that, in the opinion of the study team, acutely and/or transiently influences the PK of CAB±RPV, including acute kidney injury, hepatic insufficiency, significant drug-drug interactions, active hemolysis or symptomatic hemoglobinopathies, etc. (Note: Given the need for PK data in pregnancy, women who become pregnant while on LA IM CAB±RPV Q4W or Q8W will be allowed to participate in this study, if their clinical provider decides to continue this regimen.)

Other

  • Inability to provide informed consent
  • Unable or unwilling to comply with directly observed self-collection of DBS (e.g., unavailable or unable to use live video-streaming or time-stamped video recording technology)
  • Any uncontrolled medical, social, or mental health issue(s) that, in the opinion of the investigators, could interfere with the study participation or study outcomes (e.g., current incarceration)

Who the study is looking for

  • ≥18 years old
  • Receiving one or more antivirals for HIV treatment or prevention. This may include TFV (as TDF or TAF) and FTC (or 3TC)-based, LA (e.g., LA IM CAB±RPV Q4W or Q8W), or other antivirals (those who are transitioning to LA antivirals \[e.g., LA IM CAB±RPV Q4W or Q8W\] will also be eligible)
  • Current patient at the UCH-IDGP clinic
  • Able to comply with study procedures, including directly observed self-collection of DBS by fingerstick, Tasso-M20/Tasso+, Mitra, and/or other self-collection methods/devices, and completion of survey

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Colorado Hospital (UCHealth)
Coordinator of this site? Confirm its status
AuroraUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.